Compare Crispr Therapeutics AG (CRSP) vs iShares 1 3 Year Treasury Bond ETF (SHY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs iShares 1 3 Year Treasury Bond ETF — how do they compare? Crispr Therapeutics AG trades at $53.54 (market cap $4.88B), while iShares 1 3 Year Treasury Bond ETF trades at $81.19 (market cap $26.68B). The key difference: iShares 1 3 Year Treasury Bond ETF is far larger — about 5.5× Crispr Therapeutics AG's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, iShares 1 3 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and iShares 1 3 Year Treasury Bond ETF for 63 Days on average.
| CRSP | SHY | |
|---|---|---|
Market Cap | $4.88B | $26.68B |
Volume | 2,861,747 | 4,077,691 |
Sector | Health | Fixed Income |
52-Week High | $74.92 | $83.18 |
52-Week Low | $44.34 | $81.05 |
Typical Hold Time | 77 Days | 63 Days |
Enterprise Value | $3.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% with bearish technical signals. The company shows negative profitability metrics including -$581.6M net income and -4,101.26% net margin for 2025, though revenue is expected to grow from $0 to $11M in 2026. Recent news highlights upcoming clinical data presentations and CASGEVY's commercial potential, with analyst consensus leaning bullish despite fundamental challenges.
The outlook remains speculative with significant cash burn but promising pipeline catalysts. Investment opportunity lies in gene-editing breakthroughs and CASGEVY adoption, while risks include sustained losses, clinical trial outcomes, and competitive pressure. Wall Street maintains a $67.83 price target, suggesting 30% upside if execution improves.
SHY trades at $81.175, up 0.02% on the day, amid a bearish technical signal driven by moving averages. The stock shows neutral oscillators but faces selling pressure from the ADX indicator. Recent corporate actions include dividends scheduled for late 2026, with payouts of $0.24-$0.25 per share. The broader bond market context, with rising yields, influences sentiment around short-term bond ETFs like SHY.
The outlook for SHY is cautious due to technical bearishness and macroeconomic headwinds from rising interest rates. Opportunities exist for income-focused investors via dividends, but risks include prolonged bond market volatility and Fed policy uncertainty. Investor sentiment remains mixed, balancing yield appeal against duration risk in a higher-rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About iShares 1 3 Year Treasury Bond ETF
SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →
